Table 3.
Factors associated with pCR in patients
| Factors | pCR | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|---|
| % | OR | 95% CI | p | OR | 95% CI | p | |
| Age, years | |||||||
| < 50 | 26.5 | ||||||
| ≥ 50 | 23.3 | 1.119 | 0.504–2.810 | 0.691 | 1.329 | 0.160–11.019 | 0.792 |
| Menopausal status | |||||||
| Premenopausal | 25.0 | ||||||
| Postmenopausal | 26.5 | 0.926 | 0.378–2.269 | 0.866 | 0.330 | 0.050–5.649 | 0.601 |
| Histological grade | |||||||
| 1 or 2 | 18.5 | ||||||
| 3 | 46.2 | 0.264 | 0.079–0.888 | 0.031 | 0.272 | 0.051–2.439 | 0.126 |
| Tumor stage | |||||||
| T1–T2 | 43.5 | ||||||
| T3–T4 | 21.4 | 2.832 | 1.096–7.320 | 0.032 | 4.922 | 1.143–21.203 | 0.032 |
| Clinical nodal stage | |||||||
| N0/N1/N2 | 27.1 | ||||||
| N3 | 15.8 | 1.983 | 0.538–7.310 | 0.304 | 0.518 | 0.082–3.276 | 0.485 |
| HER2 status | |||||||
| Negative | 19.2 | ||||||
| Positive | 40.0 | 0.357 | 0.144–0.889 | 0.027 | 0.330 | 0.094–1.159 | 0.084 |
| HR status | |||||||
| Negative | 35.3 | ||||||
| Positive | 18.3 | 2.434 | 1.059–5.590 | 0.036 | 1.317 | 0.362–4.783 | 0.676 |
| Clinical stage | |||||||
| IIIA | 32.8 | ||||||
| IIIB | 20.4 | 0.385 | 0.100–1.484 | 0.166 | 0.721 | ||
| IIIC | 15.8 | 0.731 | 0.178–3.011 | 0.665 | |||
| Clinical response | |||||||
| CR | 37.8 | ||||||
| PR + SD + PD | 20.2 | 2.401 | 1.034–5.573 | 0.041 | 3.375 | 0.934–12.187 | 0.063 |
HR hormone receptor, OR odds ratio, CI confidence interval, HER2 human epidermal growth factor receptor type 2, CR complete response, PR partial response, SD stable disease, PD progressive disease, pCR pathological complete response